ArticleProceedings of the National Academy of Sciences of the United States of America2011
Requirement for complement in antibody responses is not explained by the classic pathway activator IgM.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 36 citations in OpenAlex.
- Lyme-Borreliosis Disease: IgM Epitope Mapping and Evaluation of a Serological Assay Based on Immunodominant Bi-Specific Peptides.Biomedicines · 2025Article
- Gut microbial dysbiosis activates the classical complement pathway in a short-term morphine treatment model.Gut microbes reports · 2025Article
- Harnessing IgM for solid tumor therapy: biology, engineering advances, and translational challenges.Frontiers in immunology · 2025Review
- Modelling protein-protein interactions for the design of vaccine chimeric antigens with protective epitopes.PloS one · 2025Article
- Endogenous complement-activating IgM is not required for primary antibody responses but promotes plasma cell differentiation and secondary antibody responses to a large particulate antigen in mice.Frontiers in immunology · 2023Article
- Secreted IgM: New tricks for an old molecule.Journal of leukocyte biology · 2019Review
- Role of the IgM Fc Receptor in Immunity and Tolerance.Frontiers in immunology · 2019Review
- Effects ofEvidence-based complementary and alternative medicine : eCAM · 2019Article
- Oral Vaccination With a Formulation CombiningFrontiers in cellular and infection microbiology · 2019Article
- sIgM-FcμR Interactions Regulate Early B Cell Activation and Plasma Cell Development after Influenza Virus Infection.Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- IgG3-antigen complexes are deposited on follicular dendritic cells in the presence of C1q and C3.Scientific reports · 2017Article
- Article
- Natural IgM and the Development of B Cell-Mediated Autoimmune Diseases.Critical reviews in immunology · 2016Review
- Absence of surrogate light chain results in spontaneous autoreactive germinal centres expanding V(H)81X-expressing B cells.Nature communications · 2015Article
- C-reactive protein protects mice against pneumococcal infection via both phosphocholine-dependent and phosphocholine-independent mechanisms.Infection and immunity · 2015Article
- IgG Suppresses Antibody Responses in Mice Lacking C1q, C3, Complement Receptors 1 and 2, or IgG Fc-Receptors.PloS one · 2015Article
- Complement-activating IgM enhances the humoral but not the T cell immune response in mice.PloS one · 2013Article
- The phosphocholine-binding pocket on C-reactive protein is necessary for initial protection of mice against pneumococcal infection.The Journal of biological chemistry · 2012Article
- Critical role of the IgM Fc receptor in IgM homeostasis, B-cell survival, and humoral immune responses.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Complement receptors 1 and 2 in murine antibody responses to IgM-complexed and uncomplexed sheep erythrocytes.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
Abstract
Animals lacking complement factors C1q, C2, C3, or C4 have severely impaired Ab responses, suggesting a major role for the classic pathway. The classic pathway is primarily initiated by antigen-Ab complexes. Therefore, its role for primary Ab responses seems paradoxical because only low amounts of specific Abs are present in naive animals. A possible explanation could be that the classic pathway is initiated by IgM from naive mice, binding with sufficient avidity to the antigen. To test this hypothesis, a knock-in mouse strain, Cμ13, with a point mutation in the gene encoding the third constant domain of the μ-heavy chain was constructed. These mice produce IgM in which proline in position 436 is substituted with serine, a mutation previously shown to abrogate the ability of mouse IgM to activate complement. Unexpectedly, the Ab response to sheep erythrocytes and keyhole limpet hemocyanin in Cμ13 mice was similar to that in WT mice. Thus, although secreted IgM and the classic pathway activation are both required for the normal primary Ab response, this does not require that IgM activate C. This led us to test Ab responses in animals lacking one of three other endogenous activators of the classic pathway: specific intracellular adhesion molecule-grabbing nonintegrin R1, serum amyloid P component, and C-reactive protein. Ab responses were also normal in these animals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.